APR 20, 2015 9:53 AM PDT

Brain Tumors May be New Victims of Ebola-like Virus

WRITTEN BY: Ilene Schneider
Brain tumors are notoriously difficult for most drugs to reach, but Yale researchers have found a promising but unlikely new ally against brain cancers - portions of a deadly virus similar to Ebola.
Glioma tumor cells (in red) and being destroyed in a rat brain by a chimeric virus (green) containing elements of the Lassa virus, an ebola-like pathogen.
A virus containing proteins found in the Lassa virus - like Ebola, a hemorrhagic fever virus found in some parts of Africa - not only passed through the formidable blood-brain barrier but destroyed brain tumors in mice, according to research released April 16 in the Journal of Virology.

"The chimeric virus turned out to be completely safe in animals and tended to specifically target cancer cells in the brain," said Tony van den Pol, professor of neurosurgery at the Yale School of Medicine, researcher at the Yale Cancer Center and senior author of the study.

Researchers have long been intrigued by the VSV virus, a relative of rabies, which can pass through membranes that protect the brain to infect brain tumors. The unaltered virus, however, can cause serious neurological damage. The Yale team wanted to know if portions of VSV together with portions of unrelated viruses might be safely used to attack brain tumors in mice. Some of the viruses tested, like the altered virus that contained Ebola genes, did reach the brain tumor, but did not effectively attack brain tumors. The altered Lassa virus, however, safely and effectively targeted and destroyed cancer cells within the brain. The Lassa chimeric virus targeted both gliomas and melanoma, another type of cancer that can migrate into the brain.

"We are very excited about these new chimeric viruses that contain genes from multiple viruses. They work well in targeting cancer in animals, and we hope that they will also work effectively if tested in humans," said van den Pol.

Guido Wollmann, Eugene Drokhlyansky, and Connie Cepko are other authors of the paper.

The work was funded by the NIH National Cancer Institute.

Source: Yale
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
APR 07, 2020
Cancer
APR 07, 2020
Chemo drugs are leaking into our water
With cancer as the second leading cause of death globally, it comes as a surprise that we know very little up until now ...
APR 13, 2020
Cancer
APR 13, 2020
The Unexpected Role of Mono in Cancer Progression
In the past, the go-to drugs have always been small molecules. These small molecules would interact with the cell and ac ...
APR 16, 2020
Cancer
APR 16, 2020
The Unseen Barriers Surrounding Pancreatic Cancer
Pancreatic cancer is one of the deadliest cancers in the world. With a poor five year prognosis and lack of effective tr ...
APR 19, 2020
Drug Discovery & Development
APR 19, 2020
FDA Approves New Drug for Breast Cancer
The US Food and Drug Administration has approved a new drug, known as tucatinib or Tuksya, as a treatment for advanced f ...
APR 27, 2020
Cancer
APR 27, 2020
The Tumor Suppressor and its Regulator: An Indirect Oncogene
Oncogenes, mutations in genes that promote cancer growth, have long been easy targets for cancer research due to the dir ...
MAY 13, 2020
Drug Discovery & Development
MAY 13, 2020
Approved Treatment for RET-mutant Cancers
A drug was recently approved for treating three types of RET-mutant cancers: 1) non-small cell lung cancer (NSCLC) 2) ad ...
Loading Comments...